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EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Abstract
Following an application from Pierre Fabre Medicament, submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to V0137, a ‘DHA-enriched ﬁsh oil’, and ‘helps to slow
the age-related cognitive decline in domains such as memory and executive function’. The food,
V0137, which is the subject of the health claim, is sufﬁciently characterised. The Panel considers that a
reduced loss of cognitive function is a beneﬁcial physiological effect. The applicant submitted ﬁve
human studies for the substantiation of the health claim, four of which were carried out with foods
other than V0137. No conclusions could be drawn from these four studies for the scientiﬁc
substantiation of the claim. The remaining study was a multicentre, randomised, placebo-controlled,
3-years parallel trial in 1,680 subjects of at least 70 years and at risk of cognitive decline. The
subjects were distributed to the four following study groups: (i) V0137 + multidomain intervention
(MDI; physical and cognitive exercise, nutrition recommendations); (ii) V0137 without MDI;
(iii) placebo + MDI; (iv) placebo without MDI. The primary endpoint of the study was a change in
cognitive function, as assessed by a composite cognitive score. There were no statistically signiﬁcant
differences between the study groups for changes in the composite cognitive score at 36 months. The
Panel concludes that a cause and effect relationship has not been established between the
consumption of V0137 and a reduced loss of cognitive function.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Pierre Fabre Medicament, submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of
France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an
opinion on the scientiﬁc substantiation of a health claim related to V0137, a ‘DHA-enriched ﬁsh oil’, and
‘helps to slow the age-related cognitive decline in domains such as memory and executive function’.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence. The application included a request for the protection of proprietary data.
The approach of the NDA Panel for the evaluation of the health claim is outlined in the European
Food Safety Authority (EFSA) general guidance for stakeholders on health claim applications and the
speciﬁc guidance on health claims related to functions of the nervous system, including psychological
functions.
The food that is the subject of the health claim is V0137, which, according to the applicant, is a
‘DHA-enriched ﬁsh oil’. Detailed information on the composition of the food and its manufacturing
process was provided. The Panel considers that the food, V0137, which is the subject of the health
claim, is sufﬁciently characterised.
The claimed effect proposed by the applicant is that consumption of V0137, when accompanied by
a multidomain intervention (MDI), helps to slow the age-related decline in domains such as memory
and executive function. The target population proposed by the applicant is ‘elderly (at least 70 years
old) people with primarily spontaneous memory complaints related to mild cognitive decline, and
wishing to slow their age-related cognitive decline’. Cognitive function encompasses several domains,
including memory, attention (concentration), alertness, learning, intelligence, language and problem
solving, which are well deﬁned psychological constructs. The Panel considers that a reduced loss of
cognitive function is a beneﬁcial physiological effect.
The applicant submitted ﬁve human studies for the substantiation of the health claim. Four of the
studies were carried out with foods other than V0137. The Panel considers that no conclusions can be
drawn from these four studies for the scientiﬁc substantiation of the claim.
One human study was carried out with the food, V0137, which is the subject of the health claim.
This study was a multicentre, randomised, placebo-controlled, 3-years parallel trial in 1,680 subjects of
at least 70 years and at risk of cognitive decline. The study participants were randomly distributed to
one of the four following study groups: (i) V0137 + MDI (physical and intellectual training, together
with nutrition recommendations); (ii) V0137 without MDI; (iii) placebo + MDI; (iv) placebo without
MDI.
The primary endpoint of the study was a change in cognitive function after 3 years of intervention,
as assessed by a composite cognitive score. This composite cognitive score was calculated as the sum
of z-scores from various cognitive tests, encompassing episodic memory, orientation to time and place,
speed of processing and executive function and verbal ﬂuency. Participants underwent assessments at
baseline and at visits after 6, 12, 24 and 36 months.
The main analysis was carried out on a ‘modiﬁed intention to treat (ITT)’ population (n = 1,525).
This ‘modiﬁed ITT’ population was deﬁned as all the randomised subjects who were assessed at
inclusion/baseline and at least once during follow-up. The differences in changes in the composite
cognitive score between the intervention groups were assessed using mixed models for repeated
measures. Applying a three-level linear mixed model (with ‘continuous’ time) with random centre
intercept and with random cubic subject slope and intercept, and after correction for multiple
comparisons, no statistically signiﬁcant differences were found between the study groups for changes
in the composite cognitive score at 36 months.
The applicant also provided sensitivity analyses on the primary outcome (i.e. composite cognitive
score) by considering the per protocol (PP) population (n = 1,435). The PP population excluded non-
complying subjects. For the MDI, compliance was deﬁned as an attendance rate of at least 75% of the
programme during the ﬁrst 2 months. For the consumption of the study product, only subjects who
did not take any capsule during the study were considered non-compliant and were, thus, excluded.
When applying a three-level linear mixed model (with ‘continuous’ time) with random centre intercept
and with random cubic subject slope and intercept, a signiﬁcant overall difference in the change
in composite cognitive score at 36 months was found between the four groups. However, for the
(post-hoc) group-wise comparisons no statistically signiﬁcant differences were found between any
groups after correction for multiple comparisons.
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The Panel considers that, in this study in 1,680 subjects, consumption over 3 years of V0137, in
conjunction with physical and intellectual training, did not have an effect on cognitive function in
individuals of at least 70 years with primarily spontaneous memory complaints.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of V0137 and a reduced loss of cognitive function.
V0137 and a reduced loss of cognitive function
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: V0137, a ‘DHA-enriched ﬁsh oil’,
and ‘helps to slow the age-related cognitive decline in domains such as memory and executive
function’.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of V0137, a positive assessment of its safety, nor a decision on whether V0137 is, or is not,
classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the framework
of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
Food/constituent as stated by the applicant:
• According to the applicant, the food which is the subject of the health claim is V0137, which is
a ‘DHA-enriched ﬁsh oil’.
Health relationship as claimed by the applicant:
• According to the applicant, the consumption of V0137, when accompanied by a multidomain
intervention (MDI; i.e. physical training, intellectual training and nutrition recommendations),
helps to slow the age-related decline in domains such as memory and executive function. The
applicant hypothesised that the cerebral stimulation through physical and intellectual training
may promote the use of the supplemented docosahexaenoic acid (DHA) by the brain cells,
which would result in an improved membrane ﬂuidity and synaptic plasticity, thereby
maintaining the brain cells’ functional capacities while ageing. In turn, increased concentration
of DHA in brain may allow training to exert maximal beneﬁts.
Wording of the health claim as proposed by the applicant:
• ‘V0137, in association with physical and intellectual training, helps to slow the age-related
cognitive decline in domains such as memory and executive function’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Speciﬁc conditions of use as proposed by the applicant:
• According to the applicant, two capsules of V0137 should be consumed daily, providing
1,500 mg of ‘DHA-enriched ﬁsh oil’. This supplementation should be accompanied by a MDI
comprising physical and intellectual training together with nutrition recommendations.
• The target population proposed by the applicant is ‘elderly people with primarily spontaneous
memory complaints related to mild cognitive decline, and wishing to slow their age-related
cognitive decline’. According to the applicant, mild cognitive decline is an intermediate step in
the brain ageing process characterised by cognitive deﬁcits including memory complaints.
2.1.2. Data provided by the applicant
Health claim application on V0137 and ‘helps to slow the age-related cognitive decline in domains
such as memory and executive function’ pursuant to Article 13.5 of Regulation 1924/2006, presented
in a common and structured format as outlined in the Scientiﬁc and technical guidance for the
preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel,
2011).
As outlined in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA
Panel, 2016), it is the responsibility of the applicant to provide the totality of the available evidence.
This health claim application includes a request for the protection of proprietary data (Vellas et al.,
2015), in accordance with Article 21 of Regulation (EC) No 1924/2006.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to functions of the nervous system, including
psychological functions, are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2012).
3. Assessment
3.1. Characterisation of the food/constituent
According to the applicant, the food that is the subject of the health claim is V0137, a
‘DHA-enriched ﬁsh oil’.
The Panel noted that out of the ﬁve human studies provided (Chiu et al., 2008; Yurko-Mauro et al.,
2010; Sinn et al., 2012; Lee et al., 2013; Vellas et al., 2015), only one study (Vellas et al., 2015) was
performed with V0137, while the remaining studies were carried out with DHA from microalgae or ﬁsh
oils other than V0137. Therefore, the applicant was requested to clarify the food which is the subject
of the health claim, and to consider whether the claim refers to V0137 or to DHA from all sources. In
reply, the applicant pointed out that the food, which is the subject of the claim, should be V0137, a
‘DHA-enriched ﬁsh oil’, and that the studies carried out with foods other than V0137 were submitted as
‘supportive evidence’ of the single human study performed with V0137.
Detailed information was provided on the composition of the food, its nutritional value and
speciﬁcations in relation to its acid value, peroxide value, anisidine value, tocopherol content and
microbiological quality.
An overview of the manufacturing process and information on the stability and batch-to-batch
analyses were provided.
The Panel considers that the food, V0137, which is the subject of the health claim, is sufﬁciently
characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is that consumption of V0137, when accompanied by
a MDI (i.e. physical training, intellectual training and nutrition recommendations), helps to slow the
age-related decline in domains such as memory and executive function. The target population
proposed by the applicant is ‘elderly people with primarily spontaneous memory complaints related to
mild cognitive decline, and wishing to slow their age-related cognitive decline’. Upon request for
clariﬁcation, the applicant indicated that ‘elderly people’ should be understood as deﬁned in the
protocol for the study by Vellas et al. (2015), and thus at least 70 years old.
V0137 and a reduced loss of cognitive function
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Cognitive function encompasses several domains, including memory, attention (concentration),
alertness, learning, intelligence, language and problem solving, which are well deﬁned psychological
constructs. An increase, maintenance or reduced loss of cognitive function in one or more of its
domains is a beneﬁcial physiological effect (EFSA NDA Panel, 2012).
The scientiﬁc evidence for the substantiation of health claims related to one or more speciﬁc
domains of cognitive function can be obtained from human intervention studies showing an effect on
objective measures of the speciﬁc domain(s) using standard psychometric tests (e.g. standard
‘computerised’ or ‘paper-and-pencil’ tests), established test batteries, or valid and reliable tests for the
speciﬁc domain(s) that is/are the subject of the claim (EFSA NDA Panel, 2012).
In the study (Vellas et al., 2015) submitted by the applicant, changes in cognitive function were
assessed by means of a composite cognitive score. The composite cognitive score was calculated as
the sum of z-scores for episodic memory (Free and Cued Selective Reminding Test (FCSRT)) (Grober
et al., 1988; Van der Linden et al., 2004), orientation to time and place (10 orientation items on the
mini-mental state examination (MMSE) test) (Folstein et al., 1975; Kalafat et al., 2003), speed of
processing and executive function (Digit Symbol Substitution Test from the Wechsler Adult Intelligence
Scale (WAIS)) (Wechsler, 1981, 1989) and verbal ﬂuency (Category Naming Test) (Isaacs and Akhtar,
1972; Cardebat et al., 1990). Given the variety and breadth of these tests, the Panel considers that
this composite cognitive score is an adequate outcome measure to assess changes in cognitive
function.
The Panel considers that a reduced loss of cognitive function is a beneﬁcial physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in PubMed, Science Direct and Google Scholar using
search terms such as ﬁsh oil, docosahexaenoic acid, DHA, omega-3, cognitive, cognition, brain, adult,
old, elderly in order to retrieve controlled and/or randomised clinical trials/studies, observational
studies, meta-analyses and systematic reviews in the English or French language. Additional searching
was done by hand. Studies were included if they provided at least 250 mg DHA per day and were
carried out in healthy adults aged at least 45 years who had subjective or objective memory
complaints. Studies were excluded if they were conducted in children or adults younger than 45 years,
in subjects of ≥ 45 years without subjective or objective memory complaints, or in subjects with a
clinical diagnosis of dementia or other psychological or neurological diseases. Studies which did not
assess the relationship between the intake of DHA and the claimed effect and studies of a poor
methodology were also excluded.
The applicant submitted ﬁve human studies (Chiu et al., 2008; Yurko-Mauro et al., 2010; Sinn et al.,
2012; Lee et al., 2013; Vellas et al., 2015) for the substantiation of the health claim.
The study by Yurko-Mauro et al. (2010) was performed with DHA from microalgae. The studies by
Chiu et al. (2008), Sinn et al. (2012) and Lee et al. (2013), respectively, were carried out with various
ﬁsh oil preparations other than V0137. The Panel notes that these four studies were performed with
foods other than V0137. The Panel considers that no conclusions can be drawn from these studies for
the scientiﬁc substantiation of the claim.
One human study (Vellas et al., 2015, claimed as proprietary by the applicant) was carried out with
the food, V0137, which is the subject of the health claim. This study was a multicentre, randomised,
placebo-controlled, 3-years parallel trial in 1,680 subjects (male: 35.2%, female: 64.8%) of at least
70 years and at risk of cognitive decline. In order to be eligible, subjects (enrolled at 13 memory
clinics) had to have at least one of the three following criteria: (i) a spontaneous memory complaint
expressed to their general practitioner, (ii) a limitation in one of the instrumental activities of daily
living (IADL), and/or (iii) a slow walking speed (≤ 0.8 m/sec, equivalent to 5 sec to walk 4 m). The
vast majority (99%) of the subjects were recruited after subjective memory complaints expressed to
the primary care practitioner. Subjects with a diagnosis of dementia or Alzheimer’s disease (DSM IV
criteria), any other neuropsychological disease, a MMSE score of < 24 or dependence in at least one
daily living activity (ADL < 6) were excluded.
The aim of the study was to assess whether the supplementation with V0137 in association with a
multidomain intervention, i.e. consisting of physical and intellectual training, together with nutrition
recommendations, had an effect on the change in cognitive function in subjects aged 70 years and older.
To this end, the study participants were randomly distributed to one of the four following study groups:
(i) two capsules of V0137 daily + MDI; (ii) two capsules of V0137 daily without MDI; (iii) placebo
(parafﬁn oil) + MDI; (iv) placebo without MDI. Randomisation was stratiﬁed according to site.
V0137 and a reduced loss of cognitive function
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The MDI consisted of initial training sessions in small groups (6–8 participants) in twelve 120-min
sessions for the ﬁrst 2 months. Each session included 60 min of cognitive training, 45 min of physical
training and 15 min of nutrition advice. Beginning in month 3, 60-min sessions were given each month
for the remainder of the study. These sessions included training in the following three areas: cognitive
exercise, nutrition and physical activity.
Participants underwent cognitive, functional and biological assessments at baseline and at visits
after 6, 12, 24 and 36 months (M6, M12, M24 and M36). The primary endpoint was a change in
cognitive function after 3 years of intervention, as assessed by a composite cognitive score. This
composite cognitive score was calculated as the sum of z-scores for episodic memory (Free and Cued
Selective Reminding Test (FCSRT) (Grober et al., 1988; Van der Linden et al., 2004), orientation to
time and place (10 orientation items on the MMSE test (Folstein et al., 1975; Kalafat et al., 2003)),
speed of processing and executive function (Digit Symbol Substitution Test from the WAIS (Wechsler,
1981, 1989)) and verbal ﬂuency (Category Naming Test (animals) (Isaacs and Akhtar, 1972; Cardebat
et al., 1990)).
A power analysis indicated that 201 participants were required in each group to detect with a
power of 80% (and an alpha of 0.0125), a 0.3 SD difference between the four trial arms (three
treatment groups + placebo group) in the delayed free recall score of the FCRST after 3 years of
intervention. A drop-out rate of 30% was anticipated over the 3 years of intervention and the total
sample size was adjusted accordingly. As the study subjects included were in better health than
expected by the authors (i.e. percentage of recruited subjects with CDR = 0.5 was around 30–40%
instead of the expected 50%), the sample size was increased during the trial. The study authors
proposed to change the primary assessment criterion of the study from the free recall score to a
composite cognitive score (as described above), which was approved by the Ethics Committee and the
Agence Nationale de Securite des Medicaments (ANSM) and which, according to the applicant, took
place before the unblinding of the study. Following the change in the primary endpoint, the power
calculation was revisited, and it was calculated that for a type I risk (alpha) of 0.0125 and 80% power,
it would have been necessary to include 248 subjects per group for detecting a difference of 0.3
standard deviations. In order to compensate for an expected dropout rate of 30%, it would have been
necessary to include at least 1,420 subjects in the study; this number was reached.
The total dropout rate of the study was 22.9%, and was well balanced between the four study
groups (from 22.1% to 23.7%).
According to the statistical analysis plan, the main analysis was to be carried out on a ‘modiﬁed
intention to treat’ (ITT) population. The ‘modiﬁed ITT’ population was deﬁned as all the randomised
subjects who were assessed (by means of the composite cognitive score) at inclusion/baseline and at
least once during follow-up. This ‘modiﬁed ITT’ population amounted to 1,525 subjects (out of
1,680 randomised subjects). The differences in changes in the composite cognitive score between the
intervention groups were assessed using mixed models for repeated measures (MMRM; SAS® MIXED
procedure). At baseline only, missing scores for any components of the composite score were imputed
with the median baseline score. Comparisons were made between the placebo group and each of the
three intervention groups (i.e. V0137, V0137 + MDI, placebo + MDI). The alpha signiﬁcance-level
threshold was adjusted by the Hochberg (1988) correction method in order to account for the number
of comparisons made. Applying a three-level linear mixed model (with ‘continuous’ time) with random
centre intercept and with random cubic subject slope and intercept, and after correction for multiple
comparisons, no statistically signiﬁcant differences were found between the study groups for changes
in the composite cognitive score at 36 months.
The applicant provided sensitivity analyses on the primary outcome (i.e. composite cognitive score)
by considering the per protocol (PP) population (n = 1,435). The PP population excluded non-
complying subjects. For the MDI, compliance was deﬁned as an attendance rate of at least 75% of the
programme during the ﬁrst 2 months (i.e. at least 9 of the 12 training sessions completed). For the
consumption of the study product, only subjects who did not take any capsule during the study were
considered non-compliant and were, thus, excluded. Compliance was assessed by comparing the
number of soft capsules returned to the number theoretically used by the subject and noted by the
investigator in the case report form. Compliance was 71.4% for the MDI and 84% for the consumption
of capsules. When applying a three-level linear mixed model (with ‘continuous’ time) with random
centre intercept and with random cubic subject slope and intercept, a signiﬁcant overall difference
(p = 0.0187) in the change in composite cognitive score at 36 months was found between the four
groups. However, for the (post-hoc) group-wise comparisons, no statistically signiﬁcant differences
were found between any groups after correction for multiple comparisons.
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The applicant provided further sensitivity analyses for the ‘modiﬁed ITT’ population, considering
separately the effects of the MDI (‘yes’ vs ‘no’) and of supplementation with V0137 (‘yes’ vs ‘no’) on
the composite cognitive score after 36 months. A statistically signiﬁcant effect was found for the MDI
(i.e. the composite cognitive score was improved by 0.080 (standard error = 0.033, CI 0.016–0.145,
p = 0.015) in subjects on physical and intellectual training compared to subjects without training), but
not for the food (i.e. V0137).
The applicant also provided subgroup analyses for subjects with a Clinical Dementia Rating (CDR)
score of 0.5 at enrolment, and for subjects with an MMSE score of no more than 29 (i.e. excluding
MMSE scores equal to 30) at enrolment. The Panel considers that in the absence of an effect for the
food in the main ‘modiﬁed ITT’ and sensitivity PP analyses, no conclusions can be drawn from these
post-hoc exploratory analyses.
The Panel considers that, in this study in 1,680 subjects, consumption over 3 years of V0137, in
conjunction with physical and intellectual training, did not have an effect on cognitive function in
individuals of at least 70 years with primarily spontaneous memory complaints.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of V0137 and a reduced loss of cognitive function.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food, V0137, which is the subject of the health claim, is sufﬁciently characterised.
• The claimed effect proposed by the applicant is that consumption of V0137 ‘helps to slow the
age-related decline in domains such as memory and executive function’. The target population
proposed by the applicant is ‘elderly (at least 70 years old) people with primarily spontaneous
memory complaints related to mild cognitive decline, and wishing to slow their age-related
cognitive decline’. A reduced loss of cognitive function is a beneﬁcial physiological effect.
• A cause and effect relationship has not been established between the consumption of V0137
and a reduced loss of cognitive function.
Steps taken by EFSA
1) Health claim application on V0137, a ‘DHA-enriched ﬁsh oil’, and ‘helps to slow the age-
related cognitive decline in domains such as memory and executive function’ pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0446_FR). Submitted by
Pierre Fabre Medicament, 45 place Abel Gance, 92100 Boulogne-Billancourt, France.
2) The application was received by EFSA on 15 January 2016.
3) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The application included a request for the protection of
proprietary data.
4) On 9 February 2016, during the validation process of the application, EFSA sent a request to
the applicant to provide missing information.
5) On 11 February 2016, EFSA received the missing information as submitted by the applicant.
6) The scientiﬁc evaluation procedure started on 15 February 2016.
7) On 21 April 2016, the NDA Panel agreed on a list of questions for the applicant to provide
additional information to accompany the application and the scientiﬁc evaluation was
suspended on 9 May 2016, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
8) On 24 May 2016, EFSA received the applicant’s reply and the scientiﬁc evaluation was
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
9) During its meeting on 28 June 2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to V0137 and a reduced loss
of cognitive function.
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Abbreviations
ADL activities of daily living
ANSM Agence Nationale de Securite des Medicaments
CDR Clinical Dementia Rating
DHA docosahexaenoic acid
FCSRT Free and Cued Selective Reminding Test
IADL instrumental activities of daily living
ITT intention to treat
MDI multidomain intervention
MMRM mixed models for repeated measures
MMSE mini-mental state examination
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
PP per protocol
WAIS Wechsler Adult Intelligence Scale
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